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Clinical Implications
 Anaphylaxis to antihistamines is rare. In this case, the
causative antihistamine was confirmed by repeated
clinical reactions shortly after every exposure, as well as
skin test and basophil activation tests, which were also
helpful for identifying an alternative for the patient.
TO THE EDITOR:
Antihistamines are common over-the-counter medications
used to alleviate symptoms of allergies, insomnia, nausea, and
symptoms of viral illnesses. It is exceedingly rare that these drugs
cause IgE-mediated, type I reactions. Previously, there were 2
reported cases of anaphylaxis to diphenhydramine. Mur Gimeno
et al1 reported a patient with suspected diphenhydramine-
induced anaphylaxis and negative skin test, who developed
recurrent anaphylaxis on challenge with diphenhydramine.
Nevertheless, she tolerated loratadine. Barranco et al2 reported
another case of diphenhydramine anaphylaxis in a nonatopic
patient who had positive intradermal skin test and challenge but
negative prick test and specific IgE. This patient subsequently
tolerated terfenadine, cetirizine, loratadine, and dexchlorphenir-
amine. Here we present the third case of anaphylaxis to
diphenhydramine. This is the first case to be reported that in-
volves the use of basophil activation test (BAT) in the diagnosis
and management.
A 42-year-old generally healthy man was referred for assess-
ment of recurrent anaphylaxis after taking several medications to
alleviate symptoms due to upper respiratory viral illnesses. Over
the course of many years, he experienced several episodes of
generalized, pruritic, urticarial eruption after using these medi-
cations. He became more concerned when, 3 years before his
visit to our allergy clinic, he suffered a severe reaction that
included diffuse urticaria, flushing, and angioedema, coupled
with shortness of breath and dizziness within 5 minutes after the
application of the over-the-counter intranasal drops, Coldistan.
His anaphylactic response was so intense that he was transferred
to the intensive care unit and required an adrenaline infusion.
Review of the packaging label of Coldistan revealed that the
active ingredients consisted of diphenhydramine and naphazoline
with no excipients listed. Serum tryptase during the event was
significantly elevated compared with baseline (57.9 and 6.2 mg/L,
respectively), supporting the diagnosis of anaphylaxis. Two years
later, a similar reaction recurred after he took diphenhydramine
orally for an upper respiratory illness. This time, he was stabilized
after treatments for anaphylaxis in the emergency unit.
Skin prick tests with diphenhydramine (50 mg/mL), cetirizine
(10 mg/mL), and loratadine (10 mg/mL) were performed.1 Epi-
cutaneous prick with preservative-free diphenhydramine yielded
positive skin reactivity (wheal diameters: histamine 6  6 mm,
saline 0 mm, diphenhydramine 13  19 mm with pseudopod),
whereas loratadine and cetirizine prick results were negative
(Figure 1). Diphenhydramine prick tests were negative in 6
healthy subjects. We performed BAT with serial dilution of the
drugs from neat up to 10,000 fold (BAT reagents from Flow
CAST BÜHLMANN Laboratories AG, Schönenbuch,
Switzerland). The intravenous formulation of diphenhydramine
(Omega Laboratories Q3) was used. The results showed positive
reactivity for diphenhydramine (Figure 2) and cetirizine but were
negative for chlorpheniramine and loratadine. BATs for 4 healthy
control subjects were tested negative for all 4 antihistamines.
Based on these results, the patient agreed to an open challenge to
loratadine, which he tolerated.
This patient’s presentation was most consistent with an IgE-
mediated process as evident by reproducibility of symptoms on
self-challenge, an elevated serum tryptase level after exposure,
and positive skin reactivity and BAT results.3,4 Anaphylaxis after
intranasal administration of a drug is rare, but it is possible. A
patient had even suffered cardiac arrest due to anaphylaxis after
applying intranasal chlorhexidine.5 Diphenhydramine is a low
molecular weight compound, and as such the underlying
mechanism leading to reaction is likely a hapten effect caused by
the drug itself or its metabolite(s). In the 2 previous reported















FIGURE 1. Skin prick test results at 20 minutes.




























































































































other demonstrated intradermal reactivity to diphenhydramine;
our patient showed a positive skin prick test result. It is inter-
esting to note the positive skin reactivity from an antihistamine
epicutaneous prick. Histamine is an important but not the only
mediator involved in the induction of wheal and flare response.
Other mediators also contribute, such as platelet-derived growth
factors, leukotrienes, and prostaglandins. Hence, it is likely that
the skin reaction still occurred after degranulation of cutaneous
mast cells with the antihistamine, diphenhydramine, as a stim-
ulant in this unusual case. Although details of any potential
excipient of the nasal drops and the oral formulation used during
the anaphylaxis episodes were not available, the antihistamines
we used for skin and BATs were pure without mixtures with
preservatives. Therefore, the patient most likely has hypersensi-
tivity to diphenhydramine.
BAT, a flow-based assay, is increasingly used in drug allergy
workup.4,6-9 In general, the sensitivity of BAT is higher than
serum-specific IgE testing, but results can vary depending on the
different drug items under investigation.9 Drug preparation and
optimal dose for stimulation are the most crucial steps for BAT.
Because there is no previously published protocol in the litera-
ture, we performed the assay with serial concentrations of 5, 50,
500, and 5000 mg/mL of diphenhydramine, and positive results















FIGURE 2. Basophil activation test results: diphenhydramine Q5(top left); negative control without allergen (top right); loratadine (bottom
right); and chlorphenamine (bottom left). A total of 69% of gated basophils (CCR3þ cells) showed upregulation of CD63 when stimulated
with diphenhydramine (5 mg/mL), compared with only 0.73% in the negative control plot; 1.55% and 0.96% of gated basophils showed
upregulation of CD63 when stimulated with loratadine (50 mg/mL) and chlorphenamine (4 mg/mL), respectively.
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The chemical structure of antihistamines is quite different
between groups that are unlikely to share cross-reactivity. Indeed,
including the previously reported cases, all 3 patients with
diphenhydramine allergy were successfully challenged with an
alternative antihistamine. In this case, cetirizine showed a posi-
tive result in BAT. It would be interesting to test whether pos-
itivity in BAT correlates with cetirizine intolerance. However,
the patient declined cetirizine challenge after he tolerated
loratadine.
Although severe allergic reactions to a drug commonly used
for allergy treatment are rare, one should remain vigilant of this
possibility. Skin testing and BATs showed some promise for
confirming the diagnosis of diphenhydramine allergy and iden-
tifying an alternative, although more research will be needed to
validate the methodology. Moreover, because neither skin test
nor BAT is an absolute proof of an IgE-mediated process, one
has to interpret investigation findings along with clinical pre-
sentation carefully.
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